In 2013, the company behind the gene machine called for a $1.9 million prize in the first installment of the “Discovery Challenge,” a viral social media campaign that brought awareness to the project.
The goal: To generate awareness about the use of gene machines and a “re-engineer the human genome” project to find new treatments for diseases like HIV and cancer.
The first $1 million was distributed among nine philanthropic organizations, including the National Endowment for the Humanities, the California Academy of Sciences and the American Cancer Society.
In the second installment, the prize was increased to $3.1 million, and the prize pool was expanded to 10 philanthropic institutions.
The winners include the Gene Machine Foundation, the John D. and Catherine T. MacArthur Foundation, a National Science Foundation Graduate Research Fellowship, the New York City Community Foundation and the Robert Wood Johnson Foundation.
In all, $5.9 billion in grants have been awarded to a variety of groups.
“Gene Machines will help bring about more understanding about the human condition and help us improve our lives,” said Charles Murray, a professor of bioethics at Princeton University and author of The Bell Curve.
“They will help us to understand what causes disease, what causes happiness, and what causes wealth.”
The Gene Machines’ latest project is a crowdfunding campaign to help fund a new version of the technology, called the GeneMachine Pro, which is a fully functioning gene machine.
The Pro is the same one used in the viral campaign, which raised more than $500,000 in the final days of the competition.
“We are not looking to get rich,” said Richard Sussman, the founder and chief executive of Gene Machines.
“It’s about getting a new gene, not to have it,” he said.
“And that gene is not going to be in the gene pool for long.
The new gene will be developed in the laboratory.”
The Pro’s new technology is designed to help treat cancer.
Sussmann said it would help doctors, patients and their families understand more about genetic differences between people and their cancers.
The system is designed with a small gene pool and a large amount of money, which allows researchers to design the most precise and effective treatment.
For instance, the Pro’s technology could help researchers develop a treatment that would target specific mutations in the genetic code that would cause an individual to be born with a specific mutation, rather than the general mutation.
This could give cancer patients more time to develop and control their disease and reduce their risk of spreading their disease to others.
It would also give the research community a way to study genetic variations, as well as a way for researchers to identify the best candidate treatments for their patients.
“The whole idea is to find a way of getting to know the genome so we can develop treatments that will work best for the patients, and not for the cancer cells,” Sussmans said.
For example, he said that he could design a drug that would make it easier for a person with a particular mutation to survive cancer treatment.
But for a patient with a rare variant, the drug might not work.
The research could then be tailored to fit the specific patient and would require less time to test and develop a drug.
In addition, researchers would be able to test their drugs on a variety, different patients with their Pro.
For the Pro, the researchers will have to study more than 1 million people.
The next step in the development of the new gene-based treatment will be testing it on animals, as part of the larger clinical trials.
The company has not announced any specifics about how the Pro will work in humans.
The GeneMachine’s first goal is to build a company that will sell the Pro.
The BioTune, which has raised $5 million in seed funding, aims to develop a gene-modifying treatment that could help people with rare genetic mutations.
“There is a lot of interest from other companies in creating gene therapy that can be used in humans,” said Gene Machines CEO Richard Sussedman.
“This is one of the many areas where we’re trying to create a new kind of company, and it’s the next frontier of our company.”
The company also has plans to build an automated lab to test drugs and treatments.
But Sussmen stressed that this is a long-term project.
“For the next several years, we’re not going anywhere,” he told HuffPost.
“So the goal is not to go into a market.
We’re not trying to go to the next billion-dollar company.”
And the company has already been working with universities to help them develop drugs.
In fact, Gene Machines is already working with Harvard, the University of Massachusetts at Amherst, and Emory University to develop its first drug for treating a rare genetic mutation in a mouse model.
But the company’s next goal is developing a gene therapy to treat cancer in humans and